Literature DB >> 6201553

The reactions of monoclonal antibodies with structural proteins of mumps virus.

C Orvell.   

Abstract

Mouse hybridomas producing antibodies against structural proteins of mumps virus were established by fusion of FO or SP 2/0 myeloma cells with spleen cells from BALB/c mice immunized with purified preparations of egg-grown mumps virus. Ascites fluids collected after i.p. inoculation of mice were characterized by different serologic tests. By immune precipitation tests with [35S]methionine-labeled mumps virus polypeptides, 17 clones were found to produce antibodies against the nucleocapsid protein (NP), 11 against the polymerase (P) protein, 10 against the membrane (M) protein, 12 against the fusion (F) protein, and 24 against the hemagglutinin-neuraminidase (HN) protein. Competitive binding enzyme-linked immunosorbent assay (ELISA) tests were performed to determine the reactivity of the monoclonal antibodies with different antigenic sites of each structural component. The monoclonal antibodies directed against the NP, P, and M proteins identified a minimum of 10, 10, and 9 separate antigenic sites, respectively. The 12 clones directed against F were directed against a minimum of eight separate antigenic determinants. These antibodies did not neutralize the infectivity of the virus either in the absence or presence of anti-gamma-globulin. Only low capacity to block hemolysis (HL) activity of the virus was detected in clones directed against three of the eight antigenic sites. Based on their serologic reactivity, the 24 clones directed against the HN protein could be divided into four groups. The first group of clones could not inhibit any biologic activity of the protein. The second group consisted of two clones that blocked HL but did not block hemagglutination (HA) or neuraminidase (NA) activity. The third group, which included five clones, blocked HA, NA, and HL activity of the virus and had high neutralizing capacity. These clones were directed against three distinct antigenic sites. Two of the clones directed against one antigenic site could block NA activity only when a large substrate, fetuin, was used, but not when a small substrate, neuraminlactose, was used in the test. The fourth group included five clones that could block NA but not HA activity of the virus. These clones could neutralize the infectivity of the virus and had high capacity to block HL activity. In blocking experiments, all these antibodies reacted with one antigenic site. The reaction of all clones was tested in ELISA with four different strains of mumps virus. Each strain had unique antigenic sites. Variations were found in four, three, and three different antigenic sites of the NP, P, and HN proteins, respectively.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6201553

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  23 in total

1.  Amelioration of established Sendai viral pneumonia in the nude mouse using a monoclonal antibody to the virus fusion protein.

Authors:  P Carthew; J Riley; D Dinsdale
Journal:  Br J Exp Pathol       Date:  1989-12

2.  Recent mumps outbreaks in vaccinated populations: no evidence of immune escape.

Authors:  Steven A Rubin; Malen A Link; Christian J Sauder; Cheryl Zhang; Laurie Ngo; Bert K Rima; W Paul Duprex
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Antigenic relationships between field isolates of morbilliviruses from different carnivores.

Authors:  M Blixenkrone-Möller; V Svansson; M Appel; J Krogsrud; P Have; C Orvell
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  Immunological relationships between parainfluenza virus type 4 and other paramyxoviruses studied by use of monoclonal antibodies.

Authors:  H Komada; E Klippmark; C Orvell; R E Randall; Y Ito; E Norrby
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

5.  Estimates of mumps seroprevalence may be influenced by antibody specificity and serologic method.

Authors:  Donald R Latner; Marcia McGrew; Nobia J Williams; Sun B Sowers; William J Bellini; Carole J Hickman
Journal:  Clin Vaccine Immunol       Date:  2013-12-26

6.  Neutralizing activity of the antibodies against two kinds of envelope glycoproteins of Sendai virus.

Authors:  H Tozawa; H Komatsu; K Ohkata; T Nakajima; M Watanabe; Y Tanaka; M Arifuku
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

7.  The effects of monoclonal antibodies against the hemagglutinin-neuraminidase and fusion protein on the release of Sendai virus from infected cells.

Authors:  C Orvell; K Kristensson
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

8.  Hemagglutinin-neuraminidase glycoprotein as a determinant of pathogenicity in mumps virus hamster encephalitis: analysis of mutants selected with monoclonal antibodies.

Authors:  A Löve; R Rydbeck; K Kristensson; C Orvell; E Norrby
Journal:  J Virol       Date:  1985-01       Impact factor: 5.103

9.  The F gene of rodent brain-adapted mumps virus is a major determinant of neurovirulence.

Authors:  Ken Lemon; Bertus K Rima; Stephen McQuaid; Ingrid V Allen; W Paul Duprex
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

10.  Nucleotide sequence of the gene encoding the matrix protein of mumps virus (Miyahara strain).

Authors:  K Tanabayashi; K Takeuchi; M Hishiyama; A Yamada; A Sugiura
Journal:  Virus Genes       Date:  1990-04       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.